The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.

The present invention is directed to compounds, compositions and methods for preventing, treating or curing Norovirus infection in human subjects or other animal hosts.

Disclosed are conjugates including a recognition element covalently bonded to or linked through a linker to a payload. The payload is a pharmaceutical agent (e.g., an antineoplastic agent, anti-infective agent, or anti-inflammatory agent) or a diagnostic agent. Also disclosed are methods of using the conjugates.

Disclosed herein are ETBR antagonist compounds, pharmaceutical compositions thereof, methods for treating cancers, and methods of forming tertiary lymphoid organs.

In accordance with the present subject matter there is provided a compound of Formula I wherein, R.sub.1 is substituted C.sub.1 to C.sub.10 alkyl; and R.sub.2 is substituted C.sub.1 to C.sub.10 alkyl, a process for preparing a compound of Formula I, and a gel comprising a compound of Formula I. There is also provided a process for separating a hydrophobic material from a mixture of hydrophobic and hydrophilic material using a compound of Formula I. ##STR00001##

The present invention is directed to compounds, compositions and methods for preventing, treating or curing Norovirus infection in human subjects or other animal hosts.

The disclosures herein relate to compounds of Formula (1):

##STR00001##

or a salt thereof, wherein A, Q, X, Z, L, R.sup.2, R.sup.3 and R.sup.9 are defined herein, and their use in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro.

The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.

[Task] There is provided a practical method for producing a lipidic peptide compound, the method enabling to mass-produce the lipidic peptide compound inexpensively with no need of complicated operations.

[Solution] There is provided a method to mix a non-polar solvent solution of an ester compound represented by formula (1)

##STR00001##

with a non-polar organic solvent containing an ?-amino acid compound and a base represented by formula (2)

##STR00002##

so as to produce a lipidic peptide compound or a pharmacologically acceptable salt thereof represented by formula (3).

##STR00003##

Disclosed herein are ETBR antagonist compounds, pharmaceutical compositions thereof, methods for treating cancers, and methods of forming tertiary lymphoid organs.